文献速递血栓与止血

重组活化凝血因子VII在先天性血友病伴抑制物患者家庭治疗中的安全性与疗效:临床研究与登记研究综述

Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries.
PubMed 文献 · Am J Hematol · 2017-07-19

本综述汇总16项临床研究与患者登记研究,评估重组活化凝血因子VII(rFVIIa)在先天性血友病伴抑制物(CHwI)患者家庭治疗中的安全性与疗效。14项按需治疗研究(865例患者,9024次出血事件)疗效一致较高(81%-96%),血栓事件少见(n=3);2项二级预防研究(108例患者,42,861个预防日)出血事件减少45%至59%,无血栓事件。数据支持在医生指导下启动后于家庭治疗环境中使用rFVIIa的临床实践。

要点

  • 家庭按需使用rFVIIa治疗急性出血的疗效为81%-96%,血栓事件少见(n=3)。
  • 家庭二级预防使用rFVIIa使出血事件减少45%至59%,无血栓事件。
  • 数据支持在医生指导下启动后于家庭治疗环境使用rFVIIa。

核心结论

  • 数据支持在医生指导下启动后于家庭治疗环境中给予rFVIIa的临床实践。

研究设计与样本

  • 本综述纳入16项临床研究与患者登记研究,其中14项评估急性出血事件的按需治疗(865例患者,9024次出血事件),2项评估二级预防使用(108例患者,42,861个预防日)。

主要发现

  • 按需治疗研究中疗效一致较高(81%-96%),血栓事件少见(n=3)。
  • 二级预防研究中rFVIIa与出血事件减少45%至59%相关,无血栓事件。

临床怎么用

  • 数据支持在医生指导下启动后于家庭治疗环境中给予rFVIIa的临床实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Self-administration of factor and bypassing agents by persons with hemophilia in the home setting is recommended to facilitate earlier intervention after bleeding episodes. The objective of this review was to summarize recombinant activated coagulation factor VII (rFVIIa) safety and efficacy data from clinical trials and patient registries documenting use in the home treatment setting in people with congenital hemophilia with inhibitors (CHwI). A total of 16 studies and registries were identified for inclusion; 14 evaluated on-demand treatment of acute bleeding episodes (865 patients, 9024 bleeding episodes) and 2 evaluated use for secondary prophylaxis (108 patients, 42,861 prophylaxis days). In the on-demand studies, efficacy was consistently high (81%-96%), and thrombotic events were uncommon (n = 3). In the secondary prophylaxis studies, rFVIIa was associated with a 45% to 59% reduction in bleeding episodes and no thrombotic events. These data support the clinical practice of administering rFVIIa in patients in the home treatment setting after initiation under a physician's care.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Young G, Escobar MA, Pipe SW, et al. Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries. Am J Hematol. 2017. PMID: 28589615. doi:10.1002/ajh.24811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。